2023
Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes
Ash G, Nally L, Stults-Kolehmainen M, De Los Santos M, Jeon S, Brandt C, Gulanski B, Spanakis E, Baker J, Weinzimer S, Fucito L. Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes. Clinical Journal Of Sport Medicine 2023, 33: 512-520. PMID: 36715983, PMCID: PMC10898917, DOI: 10.1097/jsm.0000000000001078.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1ExerciseHumansHypoglycemiaConceptsContinuous glucose monitoringExercise supportHealth informationDigital health informationBody mass indexType 1 diabetesCommunity-based sampleSevere hypoglycemiaMass indexPsychosocial assessmentCGM useHigh satisfaction ratingsPhysician oversightType 1Future interventionsGlucose monitoringMedical readinessMolecular biomarkersBaseline observationsInterventionSatisfaction ratingsAdultsExerciseBehavioral skillsSingle group
2022
Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O’Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews 2022, 44: 254-280. PMID: 36066457, PMCID: PMC9985411, DOI: 10.1210/endrev/bnac022.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseBlood Glucose Self-MonitoringConsensusDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInsulinConceptsInsulin delivery technologiesGlycemic goalsNear-normal glucose levelsLong-term complicationsReal-world studyHypoglycemia riskDiabetes QualityConsensus recommendationsGlucose levelsGlobal prevalenceDiabetes managementEligibility criteriaClinical practiceDelivery technologiesHealthcare providersClinical settingDiabetesInsurance coverageSignificant proportionCliniciansAid successPWDPayersComplicationsTremendous advancesAssessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdultsImpact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems
Dovc K, Battelino T, Beck RW, Sibayan J, Bailey RJ, Calhoun P, Turcotte C, Weinzimer S, Schweiger D, Nimri R, Bergenstal RM. Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems. Diabetes Technology & Therapeutics 2022, 24: 848-852. PMID: 35848991, PMCID: PMC9618368, DOI: 10.1089/dia.2022.0153.Peer-Reviewed Original ResearchBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1GlucoseHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsLived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents
Hood KK, Garcia‐Willingham N, Hanes S, Tanenbaum ML, Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell F, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium T. Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obesity And Metabolism 2022, 24: 2309-2318. PMID: 35837984, PMCID: PMC9804666, DOI: 10.1111/dom.14815.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInsulinInsulin Infusion SystemsParentsQuality of LifeTreatment OutcomeA Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G
Weinzimer S, Bailey RJ, Bergenstal RM, Nimri R, Beck RW, Schatz D, Ambler-Osborn L, Schweiger DS, von dem Berge T, Sibayan J, Johnson ML, Calhoun P, Phillip M, Bergenstal R, Phillip M, Criego A, Bergenstal R, Carlson A, Martens T, Beasley S, Johnson M, Whipple D, Hyatt J, Punel A, Grieme A, Thomas L, LaFrance A, Hasledalen C, Laffel L, Isganaitis E, Freiner E, Ambler-Osborn L, Desrochers H, Turcotte C, Naik N, Roethke L, Fisher M, Nimri R, Nevo M, Bello R, Hamou A, Hermon O, Horesh O, Shiovitch Mantzuri G, Drotz I, Yehiel N, Naveh R, Schatz D, Haller M, Albanese-O'Neill A, Sheehan E, Leey J, Smith M, Jacobsen L, Adams J, Hosford J, Whyte L, Battelino T, Dovč K, Bratina N, Šmigoc Schweiger D, Sever U, Gianini A, Murn Berkopec B, Mali B, Weinzimer S, Weyman K, Carria L, Zgorski M, Danne T, Biester T, von dem Berge T, Weiskorn J, Kordonouri O, Biester S, Aschemeier B, Remus K, Pisarek N, Sibayan J, Beck R, Mouse T, Davis J, Bailey R, Hellmann A, Reese N, Calhoun P, Strayer H, Cohen N, Henderson R, Kollman C, Kennedy J, Woodall W, Mahr I, Hood K, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C, Eggerman T. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G. Diabetes Technology & Therapeutics 2022, 24: 573-582. PMID: 35363054, PMCID: PMC9353997, DOI: 10.1089/dia.2021.0568.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1HumansHyperglycemiaHypoglycemic AgentsInsulinInsulin Infusion SystemsInsulin, Regular, HumanConceptsHybrid closed-loop systemGlucose levelsGlycemic controlGlycemic excursionsAdvanced hybrid closed-loop systemG armPostprandial glycemic excursionsPostprandial glycemic controlType 1 diabetesPostprandial glucose controlPrandial insulin deliveryTreatment armsCrossover trialGlucose controlMedtronic MiniMedSecondary analysisMeal sizeOvernight improvementInsulin deliveryHyperglycemiaOutcomesArmLevel 2HypoglycemiaPremealCongenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
Banerjee I, Raskin J, Arnoux JB, De Leon DD, Weinzimer SA, Hammer M, Kendall DM, Thornton PS. Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families. Orphanet Journal Of Rare Diseases 2022, 17: 61. PMID: 35183224, PMCID: PMC8858501, DOI: 10.1186/s13023-022-02214-y.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseBlood Glucose Self-MonitoringChildCongenital HyperinsulinismHumansHyperinsulinismInfantInfant, NewbornMonitoring, PhysiologicConceptsBlood glucose monitoringBetter outcomesUnmet needGlucose monitoringLimited treatment optionsLong-term developmental outcomesPerspectives of patientsCare of newbornsKey clinical challengeAdverse eventsSignificant morbidityPersistent hypoglycemiaTreatment optionsNeurological damageSpecialized careSpecialized centersCommon causeCurrent treatmentClinical challengeCongenital hyperinsulinismEarly diagnosisEffective treatmentNeurocognitive impairmentNew therapiesPatients
2021
Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives
Hood KK, Laffel LM, Danne T, Nimri R, Weinzimer S, Sibayan J, Bailey RJ, Schatz D, Bratina N, Bello R, Punel A, Calhoun P, Beck RW, Bergenstal RM, Phillip M. Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. Diabetes Technology & Therapeutics 2021, 23: 857-861. PMID: 34270328, PMCID: PMC9009590, DOI: 10.1089/dia.2021.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInsulinInsulin Infusion SystemsPatient Reported Outcome MeasuresYoung AdultPredictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System
Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD, Gonder-Frederick L, Robic J, Voelmle M, Conschafter K, Morris K, Barnett C, Carr K, Hellmann J, Kime M, Todd Alonso G, Slover R, Berget C, Towers L, Lange S, Buckingham B, Maahs D, Lal R, Ekhlaspour L, Norlander L, Hood K, Town M, Weir C, Smith K, Hsu L, Shinksy D, Viana J, Cengiz E, Weinzimer S, Weyman K, Carria L, Zgorski M, Ruedy K, Beck R, Borgman S, Rusnak J, Kanapka L, Kollman C, Murphy C, Arreza-Rubin G, Green N, Kovatchev B, Brown S, Anderson S, Breton M, Laffel L, Pinsker J, Levy C, Kudva Y, Wadwa R, Buckingham B, Doyle III F, Renard E, Cobelli C, Reznik Y, Arreza-Rubin G, Lum J, Beck R, Ruedy K, Janicek R, Gabrielson D. Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technology & Therapeutics 2021, 23: 475-481. PMID: 33689454, PMCID: PMC8252894, DOI: 10.1089/dia.2020.0646.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInsulinInsulin Infusion SystemsConceptsGlycemic controlLower TIROptimal glycemic controlType 1 diabetesPredictors of timeGreater improvementClinical characteristicsClinical predictorsFourth quartileMore insulinBody weightGlucose monitor dataExtension phaseMultivariate modelBolusStrongest predictorContinuous glucose monitor dataQuartileInsulinPredictorsChildrenParticipantsT1D.T1DDiabetesImpact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.
Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care 2021, 44: 983-992. PMID: 33568403, PMCID: PMC7985430, DOI: 10.2337/dc20-2125.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseBlood Glucose Self-MonitoringBrainChildChild, PreschoolDiabetes Mellitus, Type 1FemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleConceptsType 1 diabetesBrain volumeControl subjectsTotal brain volume differencesEarly-onset type 1 diabetesAge-matched control subjectsIntelligence quotientCognitive scoresWhite matter volumeBrain volume differencesContinuous glucose monitoringDiabetes groupFull-scale intelligence quotientDiabetes complicationsDiabetes controlTotal brainVerbal intelligence quotientDiabetesMatter volumeSensor glucoseCognitive testingGlucose monitoringMixed-effects modelsBrainGroup differencesA comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial
Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O'Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M, Group F. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. The Lancet 2021, 397: 208-219. PMID: 33453783, PMCID: PMC9194961, DOI: 10.1016/s0140-6736(20)32514-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1FemaleGermanyHumansHyperglycemiaInsulinInsulin Infusion SystemsIsraelMaleUnited StatesYoung AdultConceptsAdvanced hybrid closed-loop systemType 1 diabetesHybrid closed-loop systemMiniMed 670G systemGlucose levelsCrossover trialYoung adultsMultiple daily insulin injectionsSevere hypoglycaemic eventsDaily insulin injectionsComputer-generated sequencePermuted block designContinuous glucose monitoringBaseline HbACoprimary outcomesEndocrinology practiceHypoglycaemic eventsWashout periodHemoglobin levelsKidney diseaseMean ageInsulin injectionsProportion of timeContinuous glucose monitorImpaired awareness
2020
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes
Nimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine 2020, 26: 1380-1384. PMID: 32908282, DOI: 10.1038/s41591-020-1045-7.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin dose adjustmentPhysician armDose adjustmentAcademic diabetes centerInsulin pump settingsPrimary efficacy measureSevere adverse eventsTarget glucose rangeInsulin pump therapyNon-inferiority trialArtificial intelligence-based decision support systemAdverse eventsInsulin titrationDiabetes CenterEfficacy measuresPump therapyPercentage of timePercentage of readingsGlucose levelsSix monthsContinuous glucose monitoring devicesDiabetesInsulin pumpGlucose monitoring devicesEffect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi A, Cohen N, Calhoun P, Kraemer K, Breton M, Weinzimer S, Cengiz E. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care 2020, 43: 2146-2152. PMID: 32661108, PMCID: PMC7440894, DOI: 10.2337/dc20-0091.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugEquipment and SuppliesFemaleGlycemic ControlHumansHypoglycemic AgentsInsulin Infusion SystemsInsulin, Regular, HumanMaleMealsPostprandial PeriodYoung AdultConceptsControl armPremeal bolusesPostprandial plasma glucose levelsPostprandial blood glucose controlPrimary efficacy outcomeRapid-acting insulinBlood glucose controlPlasma glucose levelsType 1 diabetesLater time pointsSequential mealsEfficacy outcomesPPG levelsSecondary outcomesGlycemic excursionsMeal studyGlucose controlSubcutaneous routeInsulin delivery systemsGlucose levelsGlucose metricsHigh doseStudy daysInsulin absorptionInsulin bolus
2019
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019, 42: 1593-1603. PMID: 31177185, PMCID: PMC6973648, DOI: 10.2337/dci19-0028.Peer-Reviewed Original Research
2018
Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial
Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, Ekhlaspour L, Church MM, Weinzimer SA, Jost E, Marcal T, Andre C, Carria L, Swanson V, Lum JW, Kollman C, Woodall W, Beck RW. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care 2018, 41: dc180771. PMID: 30089663, DOI: 10.2337/dc18-0771.Peer-Reviewed Original ResearchConceptsType 1 diabetesSAP armPredictive low glucose suspendSensor-augmented pump therapyNew insulin delivery systemsRandomized Crossover StudySevere hypoglycemic eventsGlucose concentrationMin/dayMean glucose concentrationLow glucose suspendBasal-IQRebound hyperglycemiaSlim X2Glycemic controlPrimary outcomeCrossover studyMedian timeCrossover trialHypoglycemic eventsPump therapyInsulin delivery systemsPercentage of timeHypoglycemiaDiabetesOptimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System
Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care 2018, 41: dc171682. PMID: 29444895, PMCID: PMC6463622, DOI: 10.2337/dc17-1682.Peer-Reviewed Original ResearchConceptsMiniMed 670G systemHybrid closed-loop therapyTotal daily insulin doseYoung adult participantsDaily insulin doseType 1 diabetesOptimal clinical useAdult participantsClosed-loop therapyHybrid closed-loop systemPivotal trialsYounger patientsInsulin doseInsulin ratioClinical guidancePercentage of timeHCL useClinical sitesClinical useMonthsStudy phaseTrialsUse ratesParticipantsDelivery patterns
2017
International Consensus on Use of Continuous Glucose Monitoring
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017, 40: 1631-1640. PMID: 29162583, PMCID: PMC6467165, DOI: 10.2337/dc17-1600.Peer-Reviewed Original ResearchExpectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System
Iturralde E, Tanenbaum ML, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK. Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. The Science Of Diabetes Self-Management And Care 2017, 43: 223-232. PMID: 28340542, PMCID: PMC7162535, DOI: 10.1177/0145721717697244.Peer-Reviewed Original ResearchConceptsType 1 diabetesHybrid closed-loop systemFirst hybrid closed-loop systemLong-term complicationsGlycemic controlClinical trialsUS FoodDrug AdministrationMethods ThirtyDiabetesLife benefitsInsulin deliveryMental burdenT1DArtificial pancreasConclusion UsersAttitudes of individualsFocus groupsPerceived benefitsIndividualsComplicationsPancreasCliniciansAdministrationTrials
2016
Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance
Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes 2016, 18: 348-355. PMID: 27191182, DOI: 10.1111/pedi.12399.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdolescentAdolescent BehaviorAdultAlgorithmsBlood GlucoseBlood Glucose Self-MonitoringCalibrationCohort StudiesDiabetes Mellitus, Type 1Drug Dosage CalculationsDrug MonitoringGlucoseHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinPancreas, ArtificialPrecision MedicineSubcutaneous TissueYoung AdultConceptsType 1 diabetesAdolescent cohortAdult cohortHybrid closed-loop systemPump therapyPercentage of timeGlucose valuesSensor-augmented pump therapyOverall glucose controlInsulin pump therapyOverall mean percentageDose insulinGlucose controlPreliminary safetyInsulin delivery systemsInitial cohortHybrid closed-loop controlClinical practiceSecond cohortCohortMean percentageTarget rangeOverall percentageDiabetesAdults
2014
Skin and Adhesive Issues With Continuous Glucose Monitors
Englert K, Ruedy K, Coffey J, Caswell K, Steffen A, Levandoski L, Tsalikian E, Tansey M, Coffey J, Cabbage J, Salamati S, Mauras N, Fox L, Englert K, Permuy J, Sikes K, Buckingham B, Wilson D, Clinton P, Caswell K, Weinzimer S, Tamborlane W, Sherr J, Steffen A, Weyman K, Zgorski M, Tichy E, White N, Arbelaez A, Levandoski L, Starnes A, Beck R, Ruedy K, Kollman C, Xing D, Hall C, Stevens B, Grave G, Winer K, Leschek E, Becker D, Cleary P, Greenbaum C, Moran A, Steffes M, Bucksa J, Nowicki M, Makky V. Skin and Adhesive Issues With Continuous Glucose Monitors. Journal Of Diabetes Science And Technology 2014, 8: 745-751. PMID: 24876416, PMCID: PMC4764227, DOI: 10.1177/1932296814529893.Peer-Reviewed Original ResearchMeSH KeywordsAdhesivesBlood Glucose Self-MonitoringBody Surface AreaChildChild, PreschoolDiabetes Mellitus, Type 1EnvironmentFemaleHumansHumidityInfantMaleMotor ActivitySkinTemperatureConceptsContinuous glucose monitoringSkin irritationLimited body surface areaYoung childrenBody surface areaType 1 diabetesDuration of useCGM devicesReduced skin irritationSupplemental productsContinuous glucose monitorStudy groupPhysical activityImproved adherenceStudy coordinatorsCGM useSmall childrenGlucose monitoringIrritationChildrenGlucose monitorSensor wearDaily use